RAB27A‐dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance

Background and Aim Regorafenib is a potent multikinase inhibitor for the second‐line targeted therapy against hepatocellular carcinoma (HCC); however, drug resistance is emerging in clinical settings. Although cancer stem cells (CSCs) are considered as key determinate of drug sensitivity, it remains...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of gastroenterology and hepatology 2021-12, Vol.36 (12), p.3429-3437
Hauptverfasser:	Huang, Hongxia, Hou, Jue, Liu, Kewei, Liu, Qin, Shen, Liting, Liu, Biying, Lu, Qian, Zhang, Ni, Che, Linrong, Li, Jinyang, Jiang, Shan, Wang, Bin, Wen, Qinglian, Hu, Lu, Gao, Jian
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals cancer stem cell (CSC) Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Cell differentiation Cell viability Drug resistance Drug Resistance, Neoplasm - genetics exosome Exosomes Exosomes - metabolism Gene Expression Hepatocellular carcinoma hepatocellular carcinoma (HCC) Hepatocytes Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - metabolism Mice Mice, Nude Nanog Homeobox Protein - genetics Neoplastic Stem Cells - metabolism Phenotypes Phenylurea Compounds - pharmacology Polymerase chain reaction Pyridines - pharmacology rab27 GTP-Binding Proteins - genetics RAB27A regorafenib Stem cell transplantation Stem cells Tumors Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!